Michael Feldman

Affiliations: 
1955-2005 Weizmann Institute of Science, Rehovot, Israel 
Area:
cancer research, cellular immunology, developmental biology
Website:
https://www.academy.ac.il/Index2/Entry.aspx?nodeId=835&entryId=18279
Google:
"Michael Feldman"
Bio:

(1926 - 2005)
https://prabook.com/web/michael.feldman/1302406
https://books.google.com/books?id=5Eg71tOCxJoC&lpg=PA43&pg=PA43#v=onepage&q&f=false

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ruella M, Klichinsky M, Kenderian SS, et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery
Posey AD, Schwab RD, Boesteanu AC, et al. (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454
Bhoj VG, Arhontoulis D, Wertheim G, et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood
Wang E, Wang LC, Tsai CY, et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research. 3: 815-26
Tsygankova OM, Ma C, Tang W, et al. (2010) Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Molecular and Cellular Biology. 30: 3262-74
Carmon L, El-Shami KM, Paz A, et al. (2000) Novel breast-tumor-associated MUC1-derived peptides: Characterization in D(b-)/- x β2 microglobulin (β2m) null mice transgenic for a chimeric HLA- A2.1/D(b)-β2 microglobulin single chain International Journal of Cancer. 85: 391-397
El-Shami KM, Tirosh B, Popovic D, et al. (2000) Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide International Journal of Cancer. 85: 236-242
Tirosh B, el-Shami K, Vaisman N, et al. (1999) Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters. 70: 21-8
El-Shami K, Tirosh B, Bar-Haîm E, et al. (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope European Journal of Immunology. 29: 3295-3301
SELA M, FUCHS S, FELDMAN M. (1998) Specific immunologic unresponsiveness to synthetic polypeptide antigens. Science (New York, N.Y.). 139: 342-3
See more...